Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)

Iris Middeldorf, Oliver Galm, Rainhardt Osieka, Edgar Jost, James G. Herman, Stefan Wilop

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)'. Together they form a unique fingerprint.

Medicine & Life Sciences